02 Feb2015
FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
SYDNEY, Jan. 29, 2015 /CNW/ – Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)
Despite the advent of intrapartum antibiotic prophylaxis (IAP) and ongoing attempts to identify more accurate diagnostic tools, neonatal sepsis or bacteremia remains a common and potentially deadly occurrence, particularly in very-low-birth-weight (VLBW, <1500 g) babies. Sepsis causes up to 26% of all 